Just when investors thought they had seen the worst of it, the delayed Fibrogen/Astrazeneca project faces another problem.
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
Valrox leaves a disproportionate hole in Biomarin’s valuation, but gene therapy competitors shouldn’t celebrate just yet.
A shock US rejection delays approval by at least two years and makes Abbvie, which had given up rights five years ago, look smart.